Skip Navigation

Advertise|Press|Contact|FAQ|CWConnect

Bookmark/Print/Share

Home » Clinical Trials » Search Clinical Trials
Therapeutic Areas: Oncology | Hematology | Immunology

Lymphoproliferative disorders Clinical Trials

A listing of Lymphoproliferative disorders medical research trials actively recruiting patient volunteers. Use the filters below to narrow your search results.

Filter by:

Phase:

Gender:

Age:

Location:

 

Receive E-mails About New Clinical Trials!

Sign up for our FREE service and we'll send you automatic email notifications as soon as a clinical trial is posted in the medical category you're interested in.


First 1 2 Last 

Alabama

Children's Hospital of Alabama
Birmingham Alabama 35233

Patients are needed to participate in a clinical research study evaluating anti-endosialin/TEM1 monoclonal antibody MORAb-004, pharmacological study and laboratory biomarker analysis

California

Children's Hospital of Orange County
Orange California 92868

Patients are needed to participate in a clinical research study evaluating anti-endosialin/TEM1 monoclonal antibody MORAb-004, pharmacological study and laboratory biomarker analysis

University of California San Francisco Medical Center - Parnassus
San Francisco California 94143

Patients are needed to participate in a clinical research study evaluating anti-endosialin/TEM1 monoclonal antibody MORAb-004, pharmacological study and laboratory biomarker analysis

District of Columbia

Children's National Medical Center
Washington District of Columbia 20310

Patients are needed to participate in a clinical research study evaluating anti-endosialin/TEM1 monoclonal antibody MORAb-004, pharmacological study and laboratory biomarker analysis

Georgia

Children's Healthcare of Atlanta-Egleston
Atlanta Georgia 30307

Patients are needed to participate in a clinical research study evaluating anti-endosialin/TEM1 monoclonal antibody MORAb-004, pharmacological study and laboratory biomarker analysis

Illinois

Northwestern University
Chicago Illinois 60611

A Phase 1/Phase 2 clinical study for patients using brentuximab vedotin, rituximab and laboratory biomarker analysis

Ann and Robert H. Lurie Children's Hospital of Chicago
Chicago Illinois 18150

Patients are needed to participate in a clinical research study evaluating anti-endosialin/TEM1 monoclonal antibody MORAb-004, pharmacological study and laboratory biomarker analysis

Indiana

Riley Hospital for Children
Indianapolis Indiana 46202

Patients are needed to participate in a clinical research study evaluating anti-endosialin/TEM1 monoclonal antibody MORAb-004, pharmacological study and laboratory biomarker analysis

Massachusetts

Massachusetts General Hospital
Boston Massachusetts 02114

A clinical research study of bortezomib and rituximab for the treatment of Post-transplant Lymphoproliferative Disease, Solid Organ Transplant, Stem Cell Transplant (Bone Marrow Transplant) or Epstein Barr Virus Infections

Tufts University School of Medicine
Boston Massachusetts 02111

A Phase 1/Phase 2 clinical study for patients using brentuximab vedotin, rituximab and laboratory biomarker analysis

Michigan

C S Mott Children's Hospital
Ann Arbor Michigan 48109

Patients are needed to participate in a clinical research study evaluating anti-endosialin/TEM1 monoclonal antibody MORAb-004, pharmacological study and laboratory biomarker analysis

Minnesota

University of Minnesota Cancer Center-Fairview
Minneapolis Minnesota 55435

Patients are needed to participate in a clinical research study evaluating anti-endosialin/TEM1 monoclonal antibody MORAb-004, pharmacological study and laboratory biomarker analysis

Missouri

Washington University School of Medicine
St. Louis Missouri 63110

Patients are needed to participate in a clinical research study evaluating anti-endosialin/TEM1 monoclonal antibody MORAb-004, pharmacological study and laboratory biomarker analysis

New York

Columbia University Medical Center
New York New York 10032

Patients are needed to participate in a clinical research study evaluating anti-endosialin/TEM1 monoclonal antibody MORAb-004, pharmacological study and laboratory biomarker analysis

Ohio

Cincinnati Children's Hospital Medical Center
Cincinnati Ohio 45229

Patients are needed to participate in a clinical research study evaluating anti-endosialin/TEM1 monoclonal antibody MORAb-004, pharmacological study and laboratory biomarker analysis

Rainbow Babies & Children's Hospital
Cleveland Ohio 44106

Patients are needed to participate in a clinical research study evaluating anti-endosialin/TEM1 monoclonal antibody MORAb-004, pharmacological study and laboratory biomarker analysis

Pennsylvania

Children's Hospital of Philadelphia
Philadelphia Pennsylvania 19104

Patients are needed to participate in a clinical research study evaluating anti-endosialin/TEM1 monoclonal antibody MORAb-004, pharmacological study and laboratory biomarker analysis

Children's Hospital of Pittsburgh of UPMC
Pittsburgh Pennsylvania 15224

Patients are needed to participate in a clinical research study evaluating anti-endosialin/TEM1 monoclonal antibody MORAb-004, pharmacological study and laboratory biomarker analysis

Tennessee

Saint Jude Children's Research Hospital
Memphis Tennessee 38105

Patients are needed to participate in a clinical research study evaluating anti-endosialin/TEM1 monoclonal antibody MORAb-004, pharmacological study and laboratory biomarker analysis

Texas

Baylor College of Medicine
Houston Texas 77030

Patients are needed to participate in a clinical research study evaluating anti-endosialin/TEM1 monoclonal antibody MORAb-004, pharmacological study and laboratory biomarker analysis

UT MD Anderson Cancer Center
Houston Texas 77030

Patients are needed to participate in a clinical research study of SGN-35

Washington

Seattle Children's Hospital
Seattle Washington 98105

Patients are needed to participate in a clinical research study evaluating anti-endosialin/TEM1 monoclonal antibody MORAb-004, pharmacological study and laboratory biomarker analysis

Wisconsin

Midwest Children's Cancer Center
Milwaukee Wisconsin 53226

Patients are needed to participate in a clinical research study evaluating anti-endosialin/TEM1 monoclonal antibody MORAb-004, pharmacological study and laboratory biomarker analysis

Czech Republic

Hospital Motol
Prague

A clinical research study of recMAGE-A3 + AS15 ASCI and Placebo for the treatment of Urinary Bladder Neoplasms

First Faculty of Medicine, Charles University in Prague
Praha Prague

A clinical trial to evaluate treatments using Brentuximab vedotin for patients with Hodgkin Lymphoma

Krajska zdravotni, a.s. - Masarykova nemocnice v Usti nad Labem, o.z.
Usti nad Labem

A clinical research study of recMAGE-A3 + AS15 ASCI and Placebo for the treatment of Urinary Bladder Neoplasms

France

Institut Bergonié
Bordeaux

A clinical research study of recMAGE-A3 + AS15 ASCI and Placebo for the treatment of Urinary Bladder Neoplasms

Hôpital Huriez
Lille

A clinical research study of recMAGE-A3 + AS15 ASCI and Placebo for the treatment of Urinary Bladder Neoplasms

Hôpital Edouard Herriot
Lyon

A clinical research study of recMAGE-A3 + AS15 ASCI and Placebo for the treatment of Urinary Bladder Neoplasms

Hôpital Rangueil
Toulouse

A clinical research study of recMAGE-A3 + AS15 ASCI and Placebo for the treatment of Urinary Bladder Neoplasms

Germany

Universitätsklinikum Aachen
Aachen

A clinical research study of recMAGE-A3 + AS15 ASCI and Placebo for the treatment of Urinary Bladder Neoplasms

Heinrich-Heine University
Düsseldorf

A clinical research study of recMAGE-A3 + AS15 ASCI and Placebo for the treatment of Urinary Bladder Neoplasms

Universitätsklinikum Tübingen
Tübingen

A clinical research study of recMAGE-A3 + AS15 ASCI and Placebo for the treatment of Urinary Bladder Neoplasms

Italy

Università Vita e Saluta
Milano

A clinical research study of recMAGE-A3 + AS15 ASCI and Placebo for the treatment of Urinary Bladder Neoplasms

Universitaria Pisana
Pisa

A clinical research study of recMAGE-A3 + AS15 ASCI and Placebo for the treatment of Urinary Bladder Neoplasms

Japan

Chuo-ku Tokyo

A clinical trial seeking patients for a research study for the treatment of Peripheral T-Cell Lymphoma

Isehara Kanagawa

A clinical trial seeking patients for a research study for the treatment of Peripheral T-Cell Lymphoma

Kashiwa Chiba

A clinical trial seeking patients for a research study for the treatment of Peripheral T-Cell Lymphoma

Nagoya Aichi

A clinical trial seeking patients for a research study for the treatment of Peripheral T-Cell Lymphoma

Malaysia

University Malaya Medical Centre
Kuala Lumpur

A clinical trial to evaluate treatments using Brentuximab vedotin for patients with Hodgkin Lymphoma

Netherlands

NKI
Amsterdam

A clinical research study of recMAGE-A3 + AS15 ASCI and Placebo for the treatment of Urinary Bladder Neoplasms

St Antoniusziekenhuis
Nieuwegein

A clinical research study of recMAGE-A3 + AS15 ASCI and Placebo for the treatment of Urinary Bladder Neoplasms

RadboudUMC
Nijmegen

A clinical research study of recMAGE-A3 + AS15 ASCI and Placebo for the treatment of Urinary Bladder Neoplasms

Poland

Klinika Hematologii i Transplantologii, Uniwersyteckie Centrum Kliniczne
Gdansk

A clinical trial to evaluate treatments using Brentuximab vedotin for patients with Hodgkin Lymphoma

Malopolskie Centrum Medyczne S.C.
Krakow

A clinical trial to evaluate treatments using Brentuximab vedotin for patients with Hodgkin Lymphoma

Centrum Onkologii - Instytut im. Marii Sklodowskiej-Curie
Warszawa

A clinical trial to evaluate treatments using Brentuximab vedotin for patients with Hodgkin Lymphoma

Russian Federation

Institution of the Russian Academy of Medical Science Russian Oncology Research Center named after N.N. Blokhin of RAMS
Moscow

A clinical research study of recMAGE-A3 + AS15 ASCI and Placebo for the treatment of Urinary Bladder Neoplasms

Saint Petersburg State Institution of Health Care "City Multi-Field Hospital #2"
St. Petersburg

A clinical research study of recMAGE-A3 + AS15 ASCI and Placebo for the treatment of Urinary Bladder Neoplasms

Spain

Hospital Universitario A Coruña
A Coruña

A clinical research study of recMAGE-A3 + AS15 ASCI and Placebo for the treatment of Urinary Bladder Neoplasms

First 1 2 Last